"10.1371_journal.pone.0109407","plos one","2014-10-14T00:00:00Z","Luis E Morales-Buenrostro; Omar I Salas-Nolasco; Jonatan Barrera-Chimal; Gustavo Casas-Aparicio; Sergio Irizar-Santana; Rosalba Pérez-Villalva; Norma A Bobadilla","Department of Nephrology Nefrología y Metabolismo Mineral, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México City, México; Unidad de Fisiología Molecular, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, México City, México","Conceived and designed the experiments: LEMB NAB. Performed the experiments: JBCH RPV OISN GCA SIS. Analyzed the data: LEMB JBCH OISN NAB. Contributed reagents/materials/analysis tools: JBCH RPV NAB. Contributed to the writing of the manuscript: LEMB NAB.","Dr. Luis E. Morales Buenrostro is an speaker of Novartis, Roche, and Sanofi México. He also has participated in advisory boards of Boehringer Ingelheim México, Eli Lilly Mexico, Astra Zeneca México and Bristol-Myers Squibb, Mexico. Dr. Norma A. Bobadilla and Dr. Jonatan Barrera have presented patent applications in México Canada, China, Europe, and US (Diagnostic method for detecting acute kidney injury using Hsp72 as a sensitive biomarker, US 2013/0065239 A1). The rest of the authors declare that there are no financial competing interests. This does not alter the authors adherence to PLOS ONE policies on sharing data and materials.","2014","10","Luis E Morales-Buenrostro","LEMB",7,TRUE,2,5,4,NA,TRUE,TRUE,TRUE,1,"3",FALSE
